PMC:7558914 / 28779-29025
Annnotations
LitCovid_Glycan-Motif-Structure
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T47 | 59-66 | https://glytoucan.org/Structures/Glycans/G00021MO | denotes | heparin |
T48 | 59-66 | https://glytoucan.org/Structures/Glycans/G54161DR | denotes | heparin |
T49 | 97-104 | https://glytoucan.org/Structures/Glycans/G00021MO | denotes | heparin |
T50 | 97-104 | https://glytoucan.org/Structures/Glycans/G54161DR | denotes | heparin |
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
681 | 36-44 | Species | denotes | patients | Tax:9606 |
682 | 75-83 | Species | denotes | patients | Tax:9606 |
685 | 11-22 | Chemical | denotes | tocilizumab | MESH:C502936 |
686 | 59-66 | Chemical | denotes | heparin | MESH:D006493 |
687 | 97-104 | Chemical | denotes | heparin | MESH:D006493 |
691 | 121-143 | Disease | denotes | venous thromboembolism | MESH:D054556 |
LitCovid-PD-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T54 | 128-143 | Phenotype | denotes | thromboembolism | http://purl.obolibrary.org/obo/HP_0001907 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T183 | 0-246 | Sentence | denotes | The use of tocilizumab for selected patients, prophylactic heparin for all patients, therapeutic heparin for evidence of venous thromboembolism, general symptomatic and supportive care, and hospital organization were recommended in all protocols. |